

* Non compartmental *

② Statistical moment Theory

→ It is a mathematical description of discrete distribution of data.

→ It calculated from concⁿ/time data.

→ It provide unique way to study time related changes in macroscopic event.

→ Assume the drug molecule are ~~linear~~ eliminated accor. to kinetic functions

$$f(t) = C_0 e^{-kt}$$

$f(t)$ = probability density function
 t = time

Now $f(t)$ multiplied by t^m & on integration to moment curve

$$n^{th} \text{ or } m^{th} \text{ moment} = \int_0^{\infty} t^m f(t) dt \quad \text{--- (1)}$$

$f(t)$ = PDF, t = time, m = moment.

→ when $m = 0$ then yield M_0

$$M_0 = \int_0^{\infty} f(t) dt$$

If distribution is true function, then $AUC = 1$.

Now at t^{st} function M_1

$$M_1 = \int_0^{\infty} t^1 f(t) dt$$

\Rightarrow AUC at time t called AUMC
area under moment curve

Similarly M_2 & $m=2$

$$M_2 = \int_0^{\infty} t^2 f(t) dt$$

M_2 variance of distribution
 \Rightarrow Higher moments represent skewness & kurtosis distribution

Q of MRT

\Rightarrow Element of distribution curve describe the distribution of drug molecule after administration & the residence time of drug molecule in body.

\Rightarrow Here, Amount of drug in body proportional to concentration in plasma at all time points.

$$MRT = \frac{AUMC}{AUC}$$

MRT: Mean Residence time
AUMC & AUC

MRT de
in b


AUMC
drug co

AUM

AUC ab
vs fi

AUC

By trap



MRT defined as avg time spent by drug in body before elimination.


AUMC obtained from plot of product of plasma drug concⁿ & time vs. time (t) from 0 to ∞

$$AUMC = \int_0^{\infty} C \cdot t \, dt$$

AUC obtained from plot of plasma drug concⁿ vs. time (t) 0 to ∞

$$AUC = \int_0^{\infty} C \, dt$$

By trapezoidal rule calculate AUC & AUMC



Advantages

- ① Simple algebraic eqⁿ
- ② Applied to many drug that follow 1st order kinetics

Disadvantages

- ① Do not follow Non linear case
- ② also provides less info regarding Normal drug concⁿ time profile

15 Difference between compartment modelling and physiological modelling.

Compartment modelling

1. It is an hypothetical approach.

2. Experimentally simple & flexible as data collection is concerned.

3. Widely used & often the 'first model'.

4. Complex multiexponential mathematical necessary for curve fitting.

5. Data fitting required for prediction of drug concⁿ.

6. Used when little info of tissue.

7. Easy monitor with limited data.

Physiological modelling

1. It is an realistic approach.

2. Difficult experimentally since exhaustive data collection required.

3. Not widely use due to complexity.

4. Mathematical is straight forward.

5. Data fitting not required since drug concⁿ practically determine.

6. Used when tissue drug concⁿ & binding are known.

7. Exhaustive data require to monitor.

8. Mechanism of ADME
not given

8. Easy to explain ADME

9. Effect of pathological
condition on drugs
ADME not given

9. ...
... given easily

10. Commonly used for
data comparison

10. Not used for
data comparison

Q12 Define pharmacokinetic model & classify.

→ It is a mathematical model used to calculate ADME of synthetic or natural product are known as pharmacokinetic model.

→ It express the time course of drug throughout body.

→ It also predict concentration of drug in body fluid after administration of dose

→ There are 3 type of pharmacokinetic model

i) Compartment model

ii) Physiological model

iii) IVn - Compartment model

1) Compartment models

- It assumed that body consist of series of compartment
- A compartment is not real physiologic or anatomic region.
- Rate of movement of drug within compartment follows first order kinetic.
- There are 2 type of Compartment model.

(i) Mono Compartment Model

- Here this model are further divide into
 - (a) ~~Two~~ Central compartment -
 - (b) Peripheral compartment -

(a) Central compartment :- It comprise of blood and highly perfused tissue like lungs, liver, kidney, heart, brain.


(b) Peripheral :- It comprise of poorly perfused tissue like muscle, skin, adipose etc.

- Here 6 type of model present.


1. 1 compartment open, IV




2. 1 compartment open, 1st order absorption




3. 2-comp, Open, IV




u) 2-comp Open I^s ab



5. 3-comp Open IV




6. 3-comp Open, Extravascular




Dir Catenary Model.

→ It consist all compartment joint to one another



[2] physiological Model.

- Here overall drug concentration profile result from sum of processing of drug by different organ.
- The distribution depend on blood flow and the organ & its size.
- lungs, liver, brain & kidney are rapidly equilibrating tissue whereas skin, muscle etc are slowly equilibrating tissue.




[3] Non Compartment model :-

- This are independent because they do not rely upon assumption about body compartment, but rely on algebraic equation which make it less complex.

By calculating MRF the pharmacokinetic drug response.

Q13. Note on One Compartment model

- 1) The one compartment open model is the simplest model ^{which} ~~with~~ represent the body as a single, kinetically homogeneous unit that has no barriers to movement of drug.
- The final distribution equilibrium of drug in plasma and other body fluid obtained instantaneously and maintained at all times.
- 2) Here the input and output are unidirectional and that the drug can be eliminated from the body.



3) There are 3 type of One compartment model.


- One compartment open model, IV injection (Boltus)
- One compartment open model, IV infusion
- One compartment open model, Extra vascular administration which follows zero order & first order absorption

(a) One compartment open model, IV injection (Bolus)

→ when drug distributes rapidly in body given in form of rapid IV injection

↓
It takes about one to three minutes for complete circulation

↓
This shows rate of absorption is neglected



(b) General expression for rate of drug presentation to


$$\frac{dx}{dt} = -k_e x$$

where $\frac{dx}{dt}$ = rate of process
 k_e = 1st order elimination rate constant

x = Amount of drug in body

(c) One compartment open model, IV infusion

(i) Rapid IV injection is undesirable to drug produce precipitation of toxicity, thus IV infusion is beneficial due to no peaks & lows and remain stable



ii) Rate of change of amount of drug at any time (t) (dx/dt) is given as difference b/w 0^{th} order R_0 & 1^{st} order elimination $-k_e X$.


$$dx/dt = R_0 - k_e X$$

Rearrange equation

$$X = \frac{R_0 (1 - e^{-k_e t})}{k_e}$$

iii) Initially no elimination observe but after some time amount of drug in body increase until the rate of elimination equal to rate of infusion.

→ This is called steady state, plateau or equilibrium



→ Initial increase in drug concⁿ is proportional to infusion rate.

- ii) The rate of change of amount of drug in body at zero state $dX/dt = 0$

$$dX/dt = R_0 - k_e X \quad \text{--- (i)}$$


$$0 = R_0 - k_e X$$

or

$$R_0 = k_e X$$

- iii) Transform to \ln & rearranging.

$$C_{ss} = \frac{R_0}{k_e V_d} = \frac{R_0}{CL_T} = \frac{\text{Infusion Rate}}{\text{Clearance}}$$




- (c) One compartment open model, extravascular administration

- iii) Zero order absorption refers to constant absorption & thus independent of ARA & shows linear graphs.

- iv) Where first order absorption is differentiated by decreasing ARA thus shows straight line

$$\frac{dX}{dt} = \frac{dX_{ev}}{dt} - \frac{dX_e}{dt}$$



w) During Absorption

$$\frac{dX_{ev}}{dt} > \frac{dX_e}{dt}$$

w) At C_{max} $\frac{dX_{ev}}{dt} = \frac{dX_e}{dt}$

w) At Elimination $\frac{dX_{ev}}{dt} < \frac{dX_e}{dt}$

Q12 Note on Renal clearance

Q11 Note on Statistical moment theory

w) Statistical moment theory is a mathematical description of discrete ~~data~~ distribution of data.

w) It calculated from concentration v/s time data

w) It provide unique way to study the time related macroscopic event.

Assume the drug molecule eliminated according to kinetic function

$$f(t) = C_0 e^{-kt}$$

probability density function ($f(t)$) multiplied by t^m & integrated over yield the moment curve.

∴ Then moment curve show distribution

$$\mu_m \text{ or } m^{\text{th}} \text{ moment} = \int_0^{\infty} t^m f(t) dt \quad \text{--- (1)}$$

For example, when $m=0$ then yield moment is μ_0 .

$$\therefore \mu_0 = \int_0^{\infty} t^0 f(t) dt$$

$$\therefore \mu_0 = \int_0^{\infty} f(t) dt \quad \text{--- (2)}$$

If the distribution is true probability function



Area under zero moment curve is 1

Equation for 1st moment μ_1 is

$$\mu_1 = \int_0^{\infty} t^1 f(t) dt \quad \text{--- (3)}$$

∴ AUC at time (t) called AUMC (Area under moment curve).

Q10 Define term (i) Maximum concentration (ii) Therapeutic windows

(i) Maximum concentration

→ The point of maximum concentration of drug in plasma is called peak and the concentration of drug at peak is known as ~~plasma~~ peak plasma concentration.

→ It is also called peak height concentration


→ C_{max} expressed in mcg/ml

→ Peak plasma level depend on

- Administered dose

- Rate of absorption

- Rate of elimination



→ Peak shows rate of absorption equal to rate of elimination

→ Curve left to the peak is absorption phase while right to peak is elimination phase

(ii) Therapeutic windows

→ The dose range of a drug that provide safe and effective therapy with minimal adverse effect.

→ At
ineff
effec
main
wind

Q9. Noto

→ If
one

→ The
enzy


→ The
free
any

→ Drug
detox

→ The
most
that
of

→ The
climi
is

- iii) At low concentration, a drug runs the risk of being ineffective, at high concentration the risk of adverse effect, thus dosing regimens are designed to maintain drug concentration within therapeutic window.



Q9. Note on biotransformation.

- iv) It is defined as the chemical conversion of one form to another.
- v) The chemical changes are usually effected enzymatically in body.
- vi) The foreign substances that are not nutrient for the body but enter into body through any route called xenobiotics.
- vii) Drug biotransformation is one type of detoxification process.
- viii) The process of biotransformation helps to convert most lipophilic toxicant into hydrophilic metabolite that are less likely to pass through membrane of critical cell.
- ix) The loss of drug through biotransformation by eliminating organ during its passage to blood is called 1st pass metabolism.

→ The least metabolism occur in skin & most metabolism occur in liver

→ 1 Drug biotransformation reaction are classified as

(a) Phase I - functionalisation reaction

(b) Phase II - Biosynthetic reaction

(a) Phase I reaction :- In these reactions a functional group (OH , NH_2 , SH) is introduced on the parent compound usually to convert the parent drug to more polar metabolite

→ These reaction make chemical less toxic,
- more water soluble
- Easier to excrete


→ It further divided into 3 part

- 1 Oxidation :- In these reaction there is an addition of oxygen & removal of hydrogen.


→ This include cytochrome P450



(1) Reduction:- Here the substrate gains the electron on addition of hydrogen to the compound.



(2) Hydrolysis:- Here the addition of water divides the large fragment into 2 smaller fragments or molecule.



(b) Phase II reaction:- A covalent linkage is formed b/w functional group on the parent compound with endogenous substrate such as glucuronic acid, sulphate amino acid.

- These compounds are highly polar & have poor ability to cross membrane.

→ These are further divided into 6 types.


- (1) Conjugation with glucuronic acid.
- (2) Conjugation with sulphate moiety.
- (3) Conjugation with amino acid.
- (4) Conjugation with glutathione & mercapturic acid.
- (5) Acetylation.
- (6) Methylation.

Q28. (vi) Note on protein binding
"The phenomenon of complex formation of drug with a protein is known as protein binding of drug."

~ When a drug enters a body, it may undergo interaction with several tissue component of body, usually, protein, DNA or adipose.

~ Binding of drug with a protein is a reversible process because in this type of binding the weak chemical forces such as ~~hydrogen bond~~ ^{hydrogen bond}, hydrophobic bonds, ionic bond or van der Waals forces are involved.

~ Whenever irreversible binding takes place b/w protein and drug as a result of covalent binding, then carcinogenicity or tissue toxicity of the drug may occur.



of drug
protein binding

may
tissue
protein

is a
type
of
hydrophobic
acid's

place
of
activity
of drug

protein

Plasma protein Drug binding

After entry of drug into systemic circulation the first thing with which drug interact are blood component like plasma protein, Blood cell and haemoglobin.

* Mainly interact with plasma protein due to large amount and large variety.

* Binding of drug with plasma protein is reversible

Albumin > α_2 -acid glycoprotein > lipoprotein > Globulin.

⇒ Binding of drug to human serum Albumin
i) A large variety of drug → weak acid, neutral and weak base bind to HSA.

ii) 4 different site on HSA identified for drug binding.

Site 1 :- Warfarin binding site

Site 2 :- Diazepam binding site

Site 3 :- Digoxin binding site

Site 4 :- Tamoxifen binding site

⇒ Binding of drug to α -acid glycoprotein :-
 ↳ Bind to members of basic drug like

L.P. Ion

- Imipramine
- Amitriptyline
- Nortriptyline
- Lidocaine
- Propranolol
- Quinidine

⇒ Binding of drug to lipoprotein :-

↳ As per density classify as

- ① ~~chylomicron~~ chylomicron (least dense)
- ② VLDL
- ③ LDL
- ④ HDL

↳ Drugs - Diclofenac

- cyclosporin
 - chlorpromazine bind to lipoprotein
 and facilitate transport of drug to tissue

⇒ Binding of drug to albumin

↳ There are 5 type

- ① α_1 globulin :- Transcortin or CBG (Corticosteroid binding globulin)
- ② α_2 globulin :- Ceruloplasmin

protein :
g like

③ β_1 :- transferrin

④ β_2 :- Bind to Corticosteroid

⑤ γ globulin :- Bind to antigen

Q7 Note on pulmonary drug administration.

⇒ Pulmonary administration involves the inhalation of drug formulation through mouth or nose.

⇒ Since the area of alveoli is large thus provide high permeability of alveolar epithelium.

⇒ Drug used are bronchodilator;
- berclomethasone
- cromolyn.

⇒ Drug administered by inhalation either as gas or aerosol.

⇒ Here the particle size of droplet of aerosol affect the effect of drug.

⇒ 10 micron size droplet may remain in upper respiratory & do not reach pulmonary tree.

⇒ where as 0.5 micron may get to alveoli & absorbed but may excrete sometimes.

lipoprotein
to tissue

Corticosteroid

* Advantages

- ① Inhaled drug delivery put drug where it needed
- ② It require low and fraction of oral dose
- ③ Onset of action is quick
- ④ Degradation of drug in liver is avoided

* Disadvantages

- ① Irritant vapour cause inflammation of respiratory tract and increase secretion

Q2 Limitation of dissolution test

Ans

- Q5 Note on ~~in vivo~~ in vivo & in vitro correlation.
IVIVC is a scientific approach to describe the relationship b/w in vitro property of dosage form and relevant in vivo response.

Ans This concept of correlation have been developed based on their ability to reflect the plasma concentration time profile upon the administration

They are
① level
② level
③ level
④ level

- ① Level A
It represents the relationship between rate of absorption and rate of elimination
The inverse relationship is mathematically represented in same way

- Advantages
① This is the best way to act as predictive

- ② Level B
→ Utilise statistical analysis
③ Level C
→ Utilise statistical analysis

Mean in product time

They are

① Level A

② Level B

③ Level C

~~④ Level D~~

Multiple levels

Level D

① Level A :- Highest category of correlation.

It represents a perfect the point relationship between in vitro dissolution and the in vivo rate of absorption.

The in vitro dissolution and in vivo absorption rate curves are superimposable and mathematical description for both curves is same. Wagner-Nelson

of drug
also



Advantage:

① This is the highest category of correlation which act as a meaningful quality control procedure predictive of in vivo performance of formulation.

② Level B :-

Utilises the principle of statistical moment analysis. T_{mean} in vitro dissolution time (MDDT in vivo)

Utilise the principle of statistical moment analysis.

Mean in vitro dissolution time (MDDT in vitro) of product is compared to mean in vitro residence time (MRT in vivo).

For Such a correlation is not a point to point correlation, so far this reason that one cannot rely on level B.

(3) Level C: It is a single point correlation. It relate one dissolution time point to one pharmacokinetic parameter such as AUC, t_{max} or C_{max} .

level	In vitro	In vivo
A	Dissolution curve	Absorption curve
B	Mean dissolution time (MDT)	Mean Resistant time (MRT)
C	Disintegration time, dissolution rate, dissolution efficiency	C_{max} , t_{max} , K_{el} , AUC
Multiple C		

Q₂ Explain nages whitley equation.

Ans: Dissolution rate in quantitative manner was proposed by Nages & Whitley.

$$dC_b/dt = K(C_s - C_b)$$

where

dC_b/dt is dissolution rate it is linear function of difference b/w bulk concⁿ C_b at time t .

C_s is Saturation Solubility
 K = dissolution rate constant

1) This equation are modified by Nernst & Brunner

2) The modification is dissolution rate constant is directly proportional to diffusion coefficient and surface area of dissolved drug and inversely related to volume of medium and thickness of diffusion layer.

$$dC/dt = DS(C_s - C)/Vh$$

where, dC/dt = rate of diffusion

D = Diffusion coefficient

S = surface area of dissolved drug

V = Volume of dissolution medium

h = Thickness of diffusion layer

$$\frac{dC}{dt} = \frac{DS(C_s - C_b)}{Vh}$$

Q3 Difference between active transport & passive transport

(i) Active transport

① Movement of molecule from a region of low concentration to high concentration.

② Here molecule move against the concentration gradient

③ Occur via semipermeable membrane

(a) Here the energy require and in form of ATP

④ It is a selective process

⑤ Here there is requirement of carrier

⑥ It is a rapid process

⑦ It is unidirectional & affected by temperature.

⑧ It disrupt the equilibrium b/w cytosol & Extracellular environment

Passive transport

① Movement of molecule from a region of high concentration to low concentration

② Here molecule move along the concentration gradient

③ Occur even in absence of membrane

(a) Here the energy is not required

④ It is a common process

⑤ The carrier molecule is not require

⑥ It is slow process

⑦ It is bidirectional & do not affected by temperature

⑧ It maintain the equilibrium b/w cytosol & Extracellular environment

(10) Large molecule

(a) Endocytosis
blood pump
active

(b) Influence inhib

Q2 Diffusion

(iii) The

①

②

③

(iv) 10

④

⑤

⑥

⑦ Passive

(v) The

of high

concent

(10) Large molecule, insoluble molecule are transported

(10) Small & soluble molecule are transported

(11) Endocytosis, secretion into blood stream, $\text{Na}^+\text{-K}^+$ pump are example of active transport

(11) Diffusion, facilitated diffusion, osmosis are types of passive transport

(12) Influenced by metabolic inhibitor

(12) Not influenced by metabolic inhibitor

Q2 Classification of drug transport mechanism

(i) The principle for transport of drug molecule across the cell membrane are:

- (1) Passive diffusion
- (2) Active transport
- (3) Facilitated diffusion
- (4) Pore transport
- (5) Ionic or electrochemical diffusion
- (6) Ion pair
- (7) Endocytosis

(1) Passive diffusion

(i) The process by which molecule diffuse from a region of higher concentration to a region of lower concentration.

u) There is no external energy is expended

u) Fick's law explain the rate of diffusion is proportional to both surface area & concentration difference & inversely proportional to thickness of membrane

$$\text{Rate of diffusion} = \frac{\text{Surface area} \times \text{Concentration difference}}{\text{Thickness of membrane}}$$

Or

$$\frac{dQ}{dt} = \frac{DAK}{h} (C_{\text{ext}} - C)$$

where dQ/dt = rate of diffusion

D = Diffusion coefficient

A = Surface Area

K = partition coefficient

$C_{\text{ext}} - C$ = concentration difference b/w K I & plasma

h = thickness

② Active transport :-

u) It is carrier mediated transmembrane process that involve a carrier molecule

u) The transport of drug against a concentration gradient from low concentration to high concentration

u) Here energy used in the form of ATP

u) Drug enters

② Para u) less the using

u) The pressure bulk

④ Facilitated u) It is down

u) It is

u) No energy

u) Vitamin

⑤ Endocytosis

u) Process outside

u) It involve

⑥ Trans par u) The choice of drug

1) Drug like 5-Fluorouracil absorbed from GIT & enter to circulation via active transport.

2) Pore transport 100 msc

1) less than 100 molecular weight molecule are transported using ~~the~~ pore transport.

2) The driving force is constituted by the hydrostatic pressure as osmotic difference across the membrane bulk flow.

3) Facilitate transport

1) It is a carrier mediated transport system operated down the concentration gradient.

2) It is a passive transport mechanism.

3) No energy expenditure, not inhibited by metabolic poisons.

4) Vitamin B₁₂ is absorbed by this process.

4) Endocytosis

1) Process of capturing a substance or particle from outside the cell by engulfing it with cell membrane.

2) It involves pinocytosis & phagocytosis.

5) Ion pairing

1) The charges on membrane influence the permeation of drug.

- 4) These agents penetrate the membrane by forming reversible neutral complex & endogenous ion of GIT.

Q1 Define drug absorption and various route of drug absorption.

- 1) The process of transporting the drug substance from the GI lumen into systemic circulation.
- 2) If drug is poor water soluble then it will effect rate of absorption.
- 3) Rate of absorption depends on route of administration.
- 4) When drug given in IV, absorption not require.
- 5) There are certain Route of absorption like.

I Parenteral Route.


- 1) Intravenous \rightarrow 100% Bioavailability (IV)
- 2) Intramuscular (IM) \rightarrow Rapid absorption from aqueous solution.
- 3) Subcutaneous (SC) - Rapid absorption aqueous solution.

II Enteral Route.

- 1) Buccal or Sublingual (SL) :- Rapid absorption of lipid soluble drug
- 2) Oral (PO) :- Absorption may vary.
- Slower than IV or IM
- 3) Rectal (PR) :- Absorption vary from suppository

III Other Route

- 1) Transdermal :- Slow absorption
- Occlusive dressing increase absorption
- 2) Inhalation :- Rapid absorption
- Total dose absorbed is variable



Q12

Define renal clearance & wr. about determination of clearance

→ Clearance is defined as hypothetical vol. of body fluid containing drug.

- From which the drug is removed / cleared completely in specific period of time

$$Cl = \frac{\text{Elimination Rate}}{\text{Plasma drug conc}^n}$$

→ Renal Clearance :- Vol of blood / Plasma which is completely cleared of unchanged drug by kidney per unit time expressed as

$$Cl_r = \frac{\text{Rate of Urinary excretion}}{\text{Plasma drug concentration}}$$

Physiologically Renal Clearance is ratio of
"Sum of Rate of glomerulus filtration
& active secretion minus rate of reabsorption
to plasma drug concentration"

$$Cl_r = \frac{\text{Rate of filtration} + \text{Rate of secretion} - \text{Rate of reabsorption}}{\text{plasma drug concentration}}$$

Relationship b/w Cl_R value & Mechanism of Clearance

Renal clearance (ml/min)	Renal clearance Ratio	Mechanism of Renal clearance	Example
0 (least value)	0	Drug filtered & reabsorbs completely	Glucose
< 130	Above 0, Below 1	Drug filtered & reabsorbs completely	Lipophilic drug
130 (GFR)	1	Drug filtered only	Creatinine, Insulin
> 130	> 1	Drug filtered as well as secreted actively	Polar, ionic drug
550	5	Clearance equal to renal plasma flow rate	Isoflupract PAH

Factor affecting renal clearance

1. Physiological Properties of drug
Mol. size, P_{Ka} & lipid solubility
2. Plasma concentration of drug & drug that is not bound to plasma protein & excreted by filtration only linear relation b/w rate of excretion &

Plasma drug concentration

3. Distribution & Binding characteristic of drug clearance $\propto \frac{1}{\text{vol of distribution}}$

Only unbound drug appears in glomerular filtrate
Fraction of drug bound to plasma protein.

$$f_u = \frac{C_u}{C} \text{ where } f_u = \text{fraction of unbound drug in plasma}$$

$C_u = \text{conc}^n \text{ of unbound drug}$
 $C = \text{total plasma conc}^n$

4. Blood flow to kidney & renal blood flow is imp in case of drug excreted by glomerular filtration & those that are actively secreted.
5. Biological factor :- Age, Sex, species & Strain difference, ~~change~~ circadian rhythm, after drug excretion
6. Drug interaction - drug interaction result in alteration of Protein-drug binding, renal blood flow, active secretion, urine pH & forced ~~diuresis~~ diuresis
7. Diseases state - Renal impairment
- Renal dysfunction impairs elimination of drug especially those primarily excreted by kidney.

(Q1) Define drug absorption. Discuss the various factors influencing GI absorption of a drug.

→ Absorption is defined as the process of transporting the drug substance from the gastrointestinal lumen into systemic circulation.

→ By main 3 factors the absorption is affected.

① Physiological

② Physiochemical

③ Formulation

① Physiological :- It includes 9 main factors such as [RD, SE, CFI, PPF]

② Route of administration :- IV has nearly 100% of bioavailability

③ Diseases state :- Malabsorption, thyrotoxicosis, diarrhoea etc affect & decrease the rate of absorption.

③ Splanchnic blood flow:- Presence of food in stomach cause ↑ splanchnic blood flow in GI. cause decrease of absorption of Aspirin & L- dopa.

④ Enterohepatic circulation:- Enterohepatic circulation enhance drug bioavailability from absorption.

⑤ Gastric motility:- Stasis & Rapid GI motility decrease the rate of absorption.

⑥ Ionization & GI emptying:- Acidic drug absorb fast in acidic pH & Basic drug absorb fast in basic pH. Also fast GI time & prolong GI emptying time affect absorption.

⑦ Pharmacogenetic factor:- Different races have different absorption rate for substance.

e.g. Male can tolerate more alcohol than female.

⑧ Presence of ~~food~~ other substance:- In presence of iron vit C get readily absorb.

⑨ First pass metabolism:- Bioavailability ↓ in 1st pass metabolism.

② physiochemical factor [SS, D, 3P]

① Salt form of drug :- Salts of drug more readily dissolve & absorb.
e.g. Na^+ , K^+ , Penicillin.

② Solvates & hydrate :- Solvate have greater solubility & readily absorb than non solvate form.

③ Dissolution :- lipid soluble drug more rapidly absorb.

④ Particle size & Surface area :- Smaller particle size larger S.A & high absorption.

⑤ pH :- weak acid or basic drug have more effect of pH & its absorption.

① polymorphism :- when substance exists in more than one crystal lattice called polymorphism. Metastable have higher absorption.

② Formulation factor

① Disintegration time

② Manufacturing variable

③ Type of dosage form

④ Ingredient.

Q2 M.O.A of Absorption

① By 6 way the absorption done

① Passive

② Pore

③ Active

④ Endocytosis

⑤ Ion pumping

⑥ Facilitated

① Passive: The process in which molecules diffuse from a region of higher concⁿ to a lower concentration.

- No ATP use as energy

- Here the fick's law explains, "rate of diffusion is proportional to both surface area & concentration difference and inversely proportional to thickness of membrane."

Ratio of $\frac{dC}{dt}$ & $\frac{A \times \text{conc}^n \text{ difference}}{\text{thickness}}$

$$\frac{dC}{dt} = \frac{DAK}{h} (C_{\text{out}} - C)$$

- ② Pore :- less than 100 small compound pass through the pore of membrane.
- ③ Active :- Here the molecule move from lower concⁿ to higher concⁿ.
- Due to movement against concⁿ gradient ATP used as energy.
e.g. Fluorouracil.
- The carrier bind to drug & whole complex move across membrane.
- ④ Endocytosis :- capturing substance by engulfing with cell membrane & bringing into cell.
It involve pinocytosis & phagocytosis
↓ ↓
cell drinking cell eating
- This facilitated by formation of vesicles
This an active process & hence usage of energy.
This important for large molecule, protein etc.
- ⑤ Ion pair :- The agent penetrates membrane by forming reversible neutral complex.
This compound have lipophilicity & aqueous solubility.

- ② facilitated
- ↳ It involve carrier molecule to move across membrane.
 - ↳ It do not require energy to move across membrane.
 - ↳ e.g. Vit B₁₂

③ Physiological barrier of distribution Not on BBB

- ↳ There are certain barrier that prevent permeability of certain compound.
- ↳ physiological barrier is a capillary membrane b/w plasma & brain.
- ↳ There are 6 type of physiological barrier
 - ① Simple capillary endothelial barrier
 - ② Simple cell membrane barrier
 - ③ BBB
 - ④ CSF
 - ⑤ Blood placental Barrier
 - ⑥ Blood testis barrier

① Simple capillary endothelial barrier :-
Capillary are blood vessel that supply blood to most inner tissue.
Simple endothelium layer arrange on basement membrane.
- Drug with less than 600 dalton ~~now~~ pass through barrier

② Cell membrane barrier :- cell membrane is selective permeable membrane & act as barrier for certain molecule.
- Non-polar & lipid soluble can pass through.

③ BBB :- Capillary of brain consist endothelial joint together to one another by continuous tight intercellular junction called BBB

- BBB highly regulate interface that separate peripheral circulation & CNS.

- Astrocyte cell projection provide support the BBB cell.

- Molecule cross BBB by ~~not~~ paracellular or transcellular pathway.

In paracellular, ion & solute utilize concⁿ gradient to pass BBB by passive diffusion.

In transcellular diff mechanism like passive diffusion, receptor-mediated transport & transcytosis involved.

- Factor like weight, charge, solubility, S.A affect BBB crossing.
- lipid soluble & less or equal to ~~400~~ 400-600 Dalton molecular weight particle cross BBB and ~~partially~~ ~~not~~ highly ionized not cross BBB.

4) There are 5 drug delivery strategies

- a) lipophilic analogue use
- b) Use of penetration enhancer like dimethyl sulphoxide
- c) Use of carrier mediated pathway
- d) Use of osmotic pressure like intracardiac injection of hypertonic solution like mannitol or acrylamide
- e) Use of IV or IA route of administration

(4) CSF :- pair of membrane that separate blood from CSF & CSF to brain.

- colourless liquid contain glucose

form in choroid plexus of lateral ventricle, made up of capillaries covered by ependymal cell.

- molecule pass through pinocytosis..

- The flap valves prevent CSF back flow

- This valve opened when the hydrostatic pressure in subarachnoid space is greater than venous sinuses

(5) Blood placental barrier :- Placenta is an organ unite the fetus to uterus of the mother.

metabolite & nutrients are exchanged through placenta.

- It consist number of tissue layer made up of trophoblast cell & endothelium

O_2 - CO_2 & H_2O easily pass through it

- large molecule pass through vesicular transport.

(6) Blood test barrier :- It is the highest barrier in mammalian.

It divide the seminiferous epithelium into basal and the apical compartment.

Q1 Explain brief following terms.

- Mean residence time
- Hepatic clearance
- Renal clearance

Q Renal clearance.

Volume of plasma from which drug is cleared in unit time through kidney.

R.C = $\frac{\text{Rate of urinary excretion}}{\text{Plasma drug conc}^n}$

$$Cl_R = \frac{dD_u/dt}{C_p}$$

Rate of urinary excretion work on 3 main factor.

- ① filtration
- ② Secretion
- ③ Reabsorption

On putting in equation

$$Cl_R = \frac{\text{Filtration rate} + \text{Secretion} - \text{Reabsorption}}{\text{Plasma conc}^n}$$

② Hepatic Clearance

Volume of blood that perfuse the liver which is cleared of drug per unit time

$$Cl_h = Cl_t - Cl_r$$

• Here quantitative expression shows clearance of total body - clearance of Renal.

Hepatic clearance = $\frac{\text{Rate of drug cleared by liver}}{\text{plasma concn.}}$

For Organ clearance

$$Cl_h = Q_h \cdot ER_h$$

Q_h = Hepatic blood flow

ER_h = Hepatic Excretion rate

③ Mean Residence time

→ MRT describes the average time for all the drug molecule reside in body

MRT = $\frac{\text{Total residence time for drug molecule in body}}{\text{Total number of drug molecule}}$

On putting in graph the equation form as

$$MRT = \frac{AUMC}{AUC}$$

MRT :- mean Resident time

AUMC :- Area under first moment curve

AUC :- Area under zero moment curve

5

Write a note on method to enhance the bioavailability through enhancement of dissolution rate.

→ ~~SP~~ ^{adju} [MC HIM SS NN PP]

② Micro emulsion :- Optically clear, pre concentrated, isotropic, thermodynamically stable transparent system.

consist a mixture of oil, hydrophilic surfactant & solvent that dissolve poorly soluble drug

It enhance the solubility of drugs that are poorly soluble

② Co-solvency:- Solubility increase by adding water miscible solvent or co-solvent

It is mixture of water & one or more water miscible solvent that ↑ solubility

③ Hydrotophy:- It is solubilization process

- large amount of 2nd solute incorporated result in 1st solute solubility increase

- This are ionic organic salt

④ Inclusion complexes:- Biphilic drug cyclodextrin known as inclusion complexes

this are group having ^{more than} 1000 Da MW

they are cyclic oligosaccharide have polar cavity & hydrophobic surface

⑤ Micellar solubilization:- This decrease surface tension & increase dissolution of biphilic drug in aqueous medium.

Non ionic form is used e.g. castor oil, glyceride, fatty acid, ester, glycol etc.

⑥ Solid dispersion:- Poorly soluble drug dispersed in highly soluble solid hydrophilic matrix.
e.g. PVP, PEG, SLS etc.

(7) Super critical fluid:- It is novel nano-sizing technique.

This are those fluid whose temperature & pressure are more than critical temp & critical press. which allow to have liquid & gas both property.

(8) Nano ~~suspension~~ ^{suspension}:- Nano sized drug particle used that increase dissolution.

- Nano crystal, Nanopure, nanosol are some technique

(9) Nano crystallization:- A way of diminishing drug particle to size range of 1-1000 nanometer.

- Two method use bottom-up and top bottom.

(10) Particle size reduction:- S.A.Tes with less particle size & Tes solubility.

(11) PH:- By changing pH value of less water soluble drug, part of molecule that may be protonated (base) or deprotonated (acid) may acquire potential to dissolve.

(G) Explain Wagner Nelson method.

→ It is an alternative method of curve fitting method.
→ method use to estimate k_{el} from percent unabsorbed-time plot.

→ After administration of drug, the amount of drug absorbed into systemic circulation X_A is the sum of amount of drug in body X and amount of drug eliminated from body X_e .

$$X_A = X + X_e \quad \text{--- (1)}$$

Here, amount of drug in body $X = V_d C$ and amount of drug eliminated at any time t calculated as

$$X_e = k_{el} V_d [AUC]_0^t \quad \text{--- (2)}$$

By substituting X & X_e in eq (1)

$$X_A = V_d C + k_{el} V_d [AUC]_0^t \quad \text{--- (3)}$$

At time zero to infinity

~~$X_A = V_d C + k_{el} V_d [AUC]_0^t$~~

$$X_A^\infty = V_d C^\infty + k_{el} V_d [AUC]_0^\infty$$

At $t = \infty$, C^{∞} is zero.

$$X_{\infty} = K_e V_d [AUC]_{\infty}$$

Fraction of drug absorbed at time t as


$$\frac{X_A}{X_{\infty}} = \frac{V_d C + K_e V_d [AUC]_t}{K_e V_d [AUC]_{\infty}}$$

$$= \frac{C + K_e [AUC]_t}{K_e [AUC]_{\infty}}$$

\therefore To calculate percentage drug unabsorbed at any time is

$$\% \text{ ARA} = \left[1 - \frac{X_A}{X_{\infty}} \right] 100$$

$$\therefore \% \text{ ARA} = \left[1 - \frac{C + K_e [AUC]_t}{K_e [AUC]_{\infty}} \right] 100$$



7

Merit & demerit of non compartment model

Advantage

① Derivation of PK parameters is easy, because of simple algebraic equations.

② Mathematical treatment remains same, for drug or metabolite, provided elimination follows first order kinetics.

③ Drug disposition kinetics need not be described in detail.

Disadvantage

① Information regarding plasma drug concⁿ time profile is expressed as an average.

② Generally not useful for describing time course of drug in blood.

③ It is applicable only for linear pharmacokinetics.

2 Protocol of bioequivalence

1 Title.

- (a) principle investigator
- (b) project number & date

2 Study objective

3 Study design title

(a) Design

(b) Drug product

(c) Test product

(ii) Reference product

(c) Dosage regimen

(d) Sample collection

(e) Monitoring

(f) Fasting / meal schedule

(g) Analytical method

4 Study population

(a) Subjective

(b) Subject selection

(i) Medical history

(ii) Physical examination

(iii) Laboratory test

(c) Inclusion / exclusion criteria

(d) Restriction / prohibition

(e) Clinical procedure :-

(a) Dosage & drug administration

(b) Biological sampling schedule

(c) Activity of subject

(f) Ethical consideration

(a) Basic principle

(b) Institutional review board

(c) Informed consent

(d) Indication for subject withdrawal

(e) Adverse ~~of~~ reaction and emergency procedure

(g) facilities

(h) Data analysis

(a) Analytical validation procedure

(b) Statistical treatment of data


(i) Drug accountability

(j) Appendix

a)

~~Describe~~ Describe open one compartment model IV bolus administration.

- 1) Here, there is no absorption phase because drugs directly enter the systemic circulation as given IV.
- 2) Distribution of drug is rapid.



- 3) Drug administered IV, distribute in blood & other tissue & then elimination.
- 4) Hence Rate of process follows 1st order kinetics which represented as

$$\frac{dx}{dt} = -k_e x$$

$\frac{dx}{dt}$ - Rate of process
 $k_e = 1^{\text{st}}$ order rate of elimination constant

$x =$ Amount of drug at time t .

100

Latin square design in Biopharmaceutical study

~~More than two formulations to apply~~

✓

A standard approach for conducting a comparative bioavailability study is to use a randomized, balanced, cross-over design called Latin square.

In this design

- Each subject receives just once each formulation

- Each formulation is administered just once study protocol

- There are two way, three way & four way crossover

• Example

Latin square for six human volunteers

Subj	Treatment period		
	I	II	III
1	A	B	C
2	B	C	A
3	A	A	B
4	A	C	B
5	C	B	A
6	B	A	C

Advantages

- It minimize the effect of inter subject variability in study ~~by using both~~
- Minimize carry over effect
- Minimize the time effect on bioavailability

Disadvantages

- Take longer time to complete study
- Time to complete trial depend on number of formulation.
- Increased number of study period lead to high subject dropout.

(11)

Define bioavailability, Explain various method used for determination of bioavailability.

- w) Bioavailability is a measurement of rate and extent to which active ingredient are absorbed from it dosage form into systemic circulation from site of action in sufficient amount to give pharmacological response.

Method to determine bioavailability

Pharmacokinetic

Pharmacodynamic

1) plasma concentration


- t_{max}
- C_{max}
- AUC

2) Urinary drug excretion

- Amount of drug excreted in urine (D_u)
- Rate of excretion in time
- T_{max} of excretion.

1) Acute pharmacological response
2) Therapeutic response

1) Plasma drug concⁿ



① T_{max} : Time at which the maximum plasma concentration is achieved

② C_{max} : Maximum plasma concⁿ achieved after drug administered.

③ AUC : Area under plasma level time curve. It is measurement the extent of drug absorbed.

3] Urinary drug excretion

(a) D_u :- is cumulative amount of drug excreted in urine. It related directly to amount of drug absorbed.


(b) dD_u/dt :- 1st order elimination rate constant (k) & concⁿ of drug in plasma (C_p).

(c) $t_{1/2}$:- value decrease as absorption rate increase.

2] pharmacodynamic method.

(a) Acute pharmacological response :- Include change of parameter in ECG, pupil dilation, B.P etc.

(b) Therapeutic response :- It include response of drug to the diseases.



12) ~~See~~ clearance & Renal clearance
Same as Q4.

13) Same as Q1

14) What is IVIVC? Note on level of IVIVC.

IVIVC is a scientific approach to describe the relationship b/w an in vitro property of dosage form and relevant in vivo response.

This concept of correlation have been decided based on their ability to reflect the plasma concⁿ time profile upon the administration.


They are

- 1) Level A
- 2) Level B
- 3) Level C
- 4) Multiple C
- 5) Level D

1) Level A :- It represent a point to point relationship b/w in vitro dissolution and in vivo rate of absorption.

i) This level of correlation is highest category of correlation.


ii) The in vitro dissolution and in vivo rate of absorption curve are superimposable and calculated by Wagner-Nelson.




② Level B :- Utilize the principle of statistical moment theory.

- Mean in vitro dissolution time ($MDT_{in vitro}$) of product is compared to either mean in vivo resident time (MRT) or the mean in vivo dissolution time ($MDT_{in vivo}$).

= Such correlation is not point to point & thus level B is not used.




③ Level C :- It is single point correlation
ii) One dissolution time point is compared to one mean pharmacokinetic parameter such as AUC, t_{max} or C_{max} .



② Multiple correlation

It relates one or several pharmacokinetic parameters to the amount of drug dissolved at several time points of dissolution profile.



③ Level 1 correlation

It is a rank order & qualitative analysis and is not considered useful.

Level	In vitro	In vivo	Group
A	Dissolution curve	Absorption curve	
B	Mean dissolution time (MDT)	Mean Residence time (MRT)	
C	Disintegration time, dissolution rate, dissolution efficiency	C_{max} , t_{max} , AUC	

15

Explain Dissolution apparatus type I & type II

Ans The dissolution apparatus are of many type but ~~are~~ ~~per~~ main two type are listed below as per USP.

① type I :- Basket apparatus

② type II :- Paddle apparatus


① type I :- Basket

Vessel :- Borosilicate glass
- Semi hemispherical bottom
- 1000 ml capacity

Shaft :- Stainless steel 316
speed :- 50-100 rpm

Water bath :- Maintain ~~37~~ $37 \pm 0.5^\circ\text{C}$
- Thermometer

→ Rotating basket



type II :- Paddle.

Vessel :- Same

Shaft :- fused with blade at bottom


stirring element :- coated with teflon
for lab purpose
- stainless steel.

Speed :- 25-50 rpm

Water bath :- Maintain $37 \pm 0.5^\circ\text{C}$

Sinker :- platinum wire prevent rib/cap floating

- Dosage form - should remain at bottom
centre of vessel.



16) Same as ① 2

17

Regulatory requirement for conducting of ~~bioassay~~ bioequivalence study

pending

18

Non linear factor & Michaelis menton equation

→ The nonlinearity ~~factor~~ mainly cause by 4 main factors

- ① Absorption of drug
- ② Drug distribution
- ③ Drug metabolism
- ④ Drug excretion

+ The Michaelis menton equation

→ It is used to describe the kinetics of capacity limited ~~and~~ saturable process

$$-\frac{dC}{dt} = \frac{V_{max} C}{K_m + C} \quad \text{--- (1)}$$

$-dC/dt$

V_{max}
 K_m


1. when

In the

The is h

$-dc/dt$:- rate of decrease of drug concⁿ ^{with} respect to time

V_{max} :- Maximum rate of process
 K_m :- Michaelis constant



1. When the value of $K_m = C$

In this condition, equation (1) will

$$-\frac{dc}{dt} = \frac{V_{max} \cdot C}{2 \cdot C}$$

or.

$$-\frac{dc}{dt} = \frac{V_{max}}{2}$$

The equation indicate that rate of process is half ($1/2$) the maximum rate.

2. At low concⁿ ($K_m \gg C$), $K_m + C$ is approximately equal to K_m .

$$-\frac{dC}{dt} = \frac{V_{max} \cdot C}{K_m}$$

At low plasma concⁿ the elimination of most drug follows 1st order kinetic with some exceptions such as ethanol, phenytoin.

3. At high drug concⁿ ($K_m \ll C$), $K_m + C$ is equal to C .

$$-\frac{dC}{dt} = V_{max}$$

This equation indicates zero order kinetic

10) S.N on Protein Binding

last mid ans Q 8

20) Explain Ratenary & mammillary model

last mid ans Q 14

21) Absolute & relative bioavailability.
pharmacokinetic method for bioavailability measure.

Absolute

→ Measure of actual percentage of the administered dose, which is absorbed intact into systemic circulation relative to equivalent IV dose.

Relative

→ Measure of fraction of given drug that is absorbed intact in systemic circulation from a dosage form relative to established standard dosage form of that drug.

→ Compare drug exposure following extravascular administration of the tested dosage form with that IV administration.

→ Compare bioavailability of a formulation of a certain drug with another formulation of same drug.

→ Used

→ Used to characterize a drug inherent absorption properties from extravascular site.

→ Used to characterize absorption of drug from its formulation.

→ pharmacokinetic model model

→ This method is of two type

- ① plasma drug concentration
- ② urinary drug excretion.

① Plasma drug concentration

- There are main 3 type include in this method:

① T_{max} :- It is a time at which the maximum plasma concentration (C_{pmax}) is achieved after drug administration.

- At t_{max} , rate of absorption is equal to the rate of elimination.

- It is expressed in hours.